Jeb has served Nimbus as President and Chief Executive Officer and as a member of the board of directors since October 2018. He previously served as Chief Business Officer from November 2014 to October 2018 and as Chief Financial Officer from February 2017 to October 2018. Since joining Nimbus, Jeb has overseen the discovery and development of three programs into clinical testing across a range of indications, over $400M raised in equity funding, executed deals worth over $7B, and the return of over $4B in gains back to equity holders. Prior to joining Nimbus, Jeb served as the Vice President of Business Development at GSK Oncology (a subsidiary of GlaxoSmithKline plc [NYSE: GSK]) from March 2011 to October 2014, where he was responsible for identifying and concluding several critical collaborations for GSK in oncology, including the Novartis-GSK oncology integration, and spent a decade at GSK in various business development leadership roles. Prior to GSK, Jeb was a consultant at McKinsey & Company starting in September 2000–2002, then September 2004–2005, after having started his career as a pharmaceutical chemist at Pfizer Inc. (NYSE: PFE) in 1998. Jeb currently serves as a member of the board of directors at private biotechnology companies Cardurion Pharmaceuticals, Inc. and ROME Therapeutics, Inc. Jeb received bachelor’s degrees in chemistry and chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management with joint program in biomedical enterprises with the Harvard Medical School.